Prostate Cancer
Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial.
December 1, 2023
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer.
December 1, 2023
Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.
December 1, 2023
Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
November 30, 2023
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
November 30, 2023
Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
November 29, 2023
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?
November 29, 2023
Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel.
November 29, 2023
Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry.
November 29, 2023